Related Experiment Videos
Signaling protein networks as targets of new antineoplastic drugs
1Laboratory of Experimental Oncology, Department of Cell Biology and Oncology, Mario Negri Institute-Consorzio Mario Negri Sud, Santa Maria Imbaro (CH), Italy. alberti@negrisud.it
Abstract:
In-depth analysis of molecular regulatory networks in cancer holds the promise of improved knowledge of the pathophysiology of tumor cells so that it will become possible to design a detailed molecular tumor taxonomy. This knowledge will also offer new opportunities for the identification and validation of key molecular tumor targets to be exploited for novel therapeutic approaches. Some signaling proteins have already been identified as such, e.g. c-Myc, Cyclin D1, Bcl-XL, kinases and some nuclear receptors. This has led to the successful development of a few function-modulatory drugs (Glivec, SERM, Iressa), providing proof-of-principle of the validity of this approach. Further developments are likely to derive from "-omic" approaches, aimed at the understanding of signaling networks and of the mechanism of action of newfound lead molecules. High-throughput screening of small drug-like molecules from combinatorial chemical libraries or from microbial extracts will identify novel, "intelligent" drug candidates. An additional medicinal chemistry strategy (via 40-50 unit rosary-bead chains) has the potential to be much more effective than small molecules in interfering with protein-protein interactions. This may lead to considerably higher selectivity and effectiveness compared with historical approaches in drug discovery.
Insights
Understanding cancer molecular networks offers new therapeutic targets and drug discovery strategies. Advanced "-omic" approaches and novel medicinal chemistry techniques promise more selective and effective cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer pathophysiology is complex, involving intricate molecular regulatory networks.
- Identifying key molecular targets is crucial for developing novel therapeutic strategies.
- Existing targeted therapies demonstrate the potential of this approach.
Purpose of the Study:
- To explore the potential of molecular regulatory networks in cancer for improved understanding and treatment.
- To identify and validate novel molecular targets for cancer therapy.
- To investigate advanced drug discovery methods for enhanced selectivity and effectiveness.
Main Methods:
- In-depth analysis of cancer molecular regulatory networks.
- Utilizing omics approaches to understand signaling networks and drug mechanisms.
- High-throughput screening of chemical libraries and microbial extracts.
- Employing novel medicinal chemistry strategies, such as rosary-bead chains, for protein-protein interaction modulation.
Main Results:
- Established proof-of-principle for targeted cancer therapy with existing drugs.
- Identified specific molecular targets like c-Myc, Cyclin D1, Bcl-XL, kinases, and nuclear receptors.
- Demonstrated the potential of omics and advanced medicinal chemistry for discovering novel drug candidates.
Conclusions:
- Detailed molecular tumor taxonomy can be designed through network analysis.
- Novel therapeutic approaches can be developed by targeting key molecular pathways.
- Advanced screening and medicinal chemistry strategies offer superior selectivity and effectiveness in drug discovery.